Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:00325077 | Cervix | CC | maintenance of protein location in cell | 21/2311 | 65/18723 | 2.03e-05 | 3.71e-04 | 21 |
GO:004518510 | Cervix | CC | maintenance of protein location | 26/2311 | 94/18723 | 4.85e-05 | 7.34e-04 | 26 |
GO:00725955 | Cervix | CC | maintenance of protein localization in organelle | 14/2311 | 42/18723 | 3.32e-04 | 3.49e-03 | 14 |
GO:00514571 | Cervix | CC | maintenance of protein location in nucleus | 8/2311 | 23/18723 | 4.70e-03 | 2.82e-02 | 8 |
GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
GO:0045185111 | Esophagus | ESCC | maintenance of protein location | 71/8552 | 94/18723 | 3.41e-09 | 7.24e-08 | 71 |
GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
GO:0032507110 | Esophagus | ESCC | maintenance of protein location in cell | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
GO:007259517 | Esophagus | ESCC | maintenance of protein localization in organelle | 36/8552 | 42/18723 | 8.46e-08 | 1.44e-06 | 36 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:005145712 | Esophagus | ESCC | maintenance of protein location in nucleus | 20/8552 | 23/18723 | 4.97e-05 | 3.86e-04 | 20 |
GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
GO:00434332 | Esophagus | ESCC | negative regulation of DNA-binding transcription factor activity | 103/8552 | 185/18723 | 3.86e-03 | 1.57e-02 | 103 |
GO:003450411 | Liver | Cirrhotic | protein localization to nucleus | 113/4634 | 290/18723 | 5.00e-08 | 1.58e-06 | 113 |
GO:00451857 | Liver | Cirrhotic | maintenance of protein location | 46/4634 | 94/18723 | 3.31e-07 | 7.90e-06 | 46 |
GO:00325074 | Liver | Cirrhotic | maintenance of protein location in cell | 35/4634 | 65/18723 | 4.60e-07 | 1.05e-05 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAF3 | SNV | Missense_Mutation | novel | c.2000N>T | p.Ser667Ile | p.S667I | Q5VWG9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.708) | TCGA-96-7544-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TAF3 | SNV | Missense_Mutation | novel | c.683N>G | p.Leu228Arg | p.L228R | Q5VWG9 | protein_coding | deleterious(0.02) | benign(0.075) | TCGA-NK-A5CR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TAF3 | insertion | In_Frame_Ins | novel | c.1859_1860insATTCCTTCCAGG | p.Lys620_Lys621insPheLeuProGly | p.K620_K621insFLPG | Q5VWG9 | protein_coding | | | TCGA-55-A492-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAF3 | insertion | Frame_Shift_Ins | novel | c.603_604insG | p.Asp203GlyfsTer69 | p.D203Gfs*69 | Q5VWG9 | protein_coding | | | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TAF3 | insertion | Frame_Shift_Ins | novel | c.2687_2688insGC | p.Ile897GlnfsTer3 | p.I897Qfs*3 | Q5VWG9 | protein_coding | | | TCGA-34-2609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
TAF3 | SNV | Missense_Mutation | novel | c.616N>A | p.Asp206Asn | p.D206N | Q5VWG9 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-CR-7370-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAF3 | SNV | Missense_Mutation | rs748291820 | c.1498C>T | p.Pro500Ser | p.P500S | Q5VWG9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.753) | TCGA-P3-A5QF-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cetuximab | PD |
TAF3 | insertion | Frame_Shift_Ins | rs754261495 | c.1863_1864insTTCCTTCCAG | p.Asp622PhefsTer5 | p.D622Ffs*5 | Q5VWG9 | protein_coding | | | TCGA-F7-8298-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TAF3 | SNV | Missense_Mutation | novel | c.2357N>T | p.Ala786Val | p.A786V | Q5VWG9 | protein_coding | tolerated_low_confidence(0.09) | benign(0.001) | TCGA-V1-A9OH-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | SD |
TAF3 | SNV | Missense_Mutation | novel | c.938N>A | p.Gly313Glu | p.G313E | Q5VWG9 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |